Aptamers as tools for target validation

Current Opinion in Chemical Biology

Volumn 9, Issue 4, 2005, Pages 336-342

  Blank, Michael ^a   Blind, Michael ^a  

^a NascaCell Technologies AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA; MESSENGER RNA; NUCLEIC ACID; PEGAPTANIB; RNA; SMALL INTERFERING RNA;

CELL CULTURE; CLINICAL TRIAL; DRUG TARGETING; ENZYME SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEOMICS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOMATION; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDES; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 22544477581     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.06.011     Document Type: Review

References (39)

1. S. Harris, and S.M. Foord Transgenic gene knock-outs: functional genomics and therapeutic target selection Pharmacogenomics 1 2000 433 443
2. C.A. Power Knock out models to dissect chemokine receptor function in vivo J Immunol Methods 273 2003 73 82
3. R. Schlingensiepen, and K.H. Schlingensiepen Antisense oligodeoxynucleotides - highly specific tools for basic research and pharmacotherapy R. Schlingensiepen K.H. Schlingensiepen Antisense - From Technology to Therapy 1997 Blackwell 3 28
4. J. Kurreck Antisense technologies. Improvement through chemical modifications Eur J Biochem 270 2003 1628 1644
5. S.M. Elbashir, W. Lendeckel, and T. Tuschl RNA interference is mediated by 21- and 22-nucleotide RNAs Genes Dev 15 2001 188 200
6. T. Tuschl, and A. Borkhardt Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy Mol Interv 2 2002 158 167
7. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
8. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
9. S.D. Jayasena Aptamers: an emerging class of molecules that rival antibodies in diagnostics Clin Chem 45 1999 1628 1650
10. K. Thiel Oligo oligarchy - the surprisingly small world of aptamers Nat Biotechnol 22 2004 649 651
11. G. Mayer, and A. Jenne Aptamers in research and development BioDrugs 18 2004 351 359
12. J.C. Cox, P. Rudolph, and A.D. Ellington Automated RNA selection Biotechnol Prog 14 1998 845 850
13. J.C. Cox, and A.D. Ellington Automated selection of anti-protein aptamers Bioorg Med Chem 9 2001 2525 2531
14. J.C. Cox, A. Hayhurst, J. Hesselberth, T.S. Bayer, G. Georgiou, and A.D. Ellington Automated selection of aptamers against protein targets translated in vitro: from gene to aptamers Nucleic Acids Res 30 2002 e108
15. J.C. Cox, M. Rajendran, T. Riedel, E.A. Davidson, L.J. Sooter, T.S. Bayer, M. Schmitz-Brown, and A.D. Ellington Automated acquisition of aptamer sequences Comb Chem High Throughput Screen 5 2002 289 299
16. E.N. Brody, and L. Gold Aptamers as therapeutic and diagnostic agents J Biotechnol 74 2000 5 13
17. C. Bock, M. Coleman, B. Collins, J. Davis, G. Foulds, L. Gold, C. Greef, J. Heil, J.S. Heilig, and B. Hicke Photoaptamer arrays applied to multiplexed proteomic analysis Proteomics 4 2004 609 618
18. D. Eulberg, K. Buchner, C. Maasch, and S. Klussmann Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist Nucleic Acids Res 33 2005 e45
19. M. Blind, D. Faulhammer, and G. Mayer Speeding up functional genomics by automated selection of intramers Am Genomics/Proteomics Technol Jul/Aug 2002 28 33
20. S.D. Seiwert, N.T. Stines, S. Aigner, N.G. Ahn, and O.C. Uhlenbeck RNA aptamers as pathway-specific MAP kinase inhibitors Chem Biol 7 2000 833 843
21. S.E. Lupold, B.J. Hicke, Y. Lin, and D.S. Coffey Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen Cancer Res 62 2002 4029 4033 An article describing the simultaneous selection of different aptamers, which inhibit their target by competitive and non-competitive mechanisms.
22. M. Kimoto, M. Shirouzu, S. Mizutani, H. Koide, Y. Kaziro, I. Hirao, and S. Yokoyama Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation Eur J Biochem 269 2002 697 704
23. A.C. Gavin, M. Bosche, R. Krause, P. Grandi, M. Marzioch, A. Bauer, J. Schultz, J.M. Rick, A.M. Michon, and C.M. Cruciat Functional organization of the yeast proteome by systematic analysis of protein complexes Nature 415 2002 141 147
24. T. Ostendorf, U. Kunter, F. Eitner, A. Loos, H. Regele, D. Kerjaschki, D.D. Henninger, N. Janjic, and J. Floege VEGF(165) mediates glomerular endothelial repair J Clin Invest 104 1999 913 923
25. S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, S. Amano, Y. Ogura, T. Hida, Y. Oguchi, J. Ambati, and J.W. Miller VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization J Exp Med 198 2003 483 489
26. T. Ostendorf, U. Kunter, C. Van Roeyen, S. Dooley, N. Janjic, J. Ruckman, F. Eitner, and J. Floege The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system J Am Soc Nephrol 13 2002 658 667
27. S. Helmling, C. Maasch, D. Eulberg, K. Buchner, W. Schroder, C. Lange, S. Vonhoff, B. Wlotzka, M.H. Tschop, S. Rosewicz, and S. Klussmann Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer Proc Natl Acad Sci USA 101 2004 13174 13179 Interesting paper describing the development and in vivo use of enantiomeric aptamers, called 'Spiegelmers', which are an alternative to the usual 2′-ribose modifications and are extremely stable against degradation by nucleases.
28. S.H. Jeon, B. Kayhan, T. Ben-Yedidia, and R. Arnon A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin J Biol Chem 279 2004 48410 48419
29. M. Khati, M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers J Virol 77 2003 12692 12698
30. S. Santulli-Marotto, S.K. Nair, C. Rusconi, B. Sullenger, and E. Gilboa Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res 63 2003 7483 7489 Example of how aptamers can be multimerized by a simple annealing step improving their avidity and biological activity in vivo.
31. S.M. Nimjee, C.P. Rusconi, R.A. Harrington, and B.A. Sullenger The potential of aptamers as anticoagulants Trends Cardiovasc Med 15 2005 41 45
32. P. Burgstaller, A. Jenne, and M. Blind Aptamers and aptazymes: accelerating small molecule drug discovery Curr Opin Drug Discov Devel 5 2002 690 700
33. P. Burgstaller, A. Girod, and M. Blind Aptamers as tools for target prioritization and lead identification Drug Discov Today 7 2002 1221 1228
34. C.P. Rusconi, E. Scardino, J. Layzer, G.A. Pitoc, T.L. Ortel, D. Monroe, and B.A. Sullenger RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94 An important work describing the modulation of binding activity by antisense probes allowing the tight control of aptamer activity.
35. C.P. Rusconi, J.D. Roberts, G.A. Pitoc, S.M. Nimjee, R.R. White, G. Quick Jr., E. Scardino, W.P. Fay, and B.A. Sullenger Antidote-mediated control of an anticoagulant aptamer in vivo Nat Biotechnol 22 2004 1423 1428 An excellent study demonstrating that the antisense (antidote) mediated inhibition of aptamer activity works extremely efficient in vivo. The work provides the basis of a tightly controllable system to modulate aptamer activity in target validation or therapeutic applications.
36. D.H. Burke, and D.G. Nickens Expressing RNA aptamers inside cells to reveal proteome and ribonome function Brief Funct Genomic Proteomic 1 2002 169 188
37. M.G. Theis, A. Knorre, B. Kellersch, J. Moelleken, F. Wieland, W. Kolanus, and M. Famulok Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2 Proc Natl Acad Sci USA 101 2004 11221 11226 An important example in which aptamers were used to dissect signal transduction pathways. Moreover, it is the first study to directly compare the effects of siRNA and aptamers on the same target, demonstrating how both technologies can complement one another.
38. Eyetech Study Group Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 22 2002 143 152
39. G. Mayer, M. Grättinger, and M. Blind Aptamers: multifunctional tools for target validation and drug discovery Drug Plus Int 2 2003 6 10